[Antiobesity drugs--new limitations].
Nau
Jean-Yves
JY
D019440:Anti-Obesity Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects; D003863:Depression / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects; D009767:Obesity, Morbid / Q000188:drug therapy*; D000077403:Orlistat; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D013405:Suicide; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077403:Orlistat; D000077285:Rimonabant; C058254:sibutramine